During the forecast period 2023 to 2033, the Carcinoid tumor syndrome management market is expected to grow at a value of 10.9% CAGR, according to Future Market Insights. By the year 2033, the global market for Carcinoid tumor syndrome management is expected to rise up to a market valuation of US$ 4993 Million. Growth of the market can be attributed to increasing prevalence of the disease, advancements in diagnosis and treatment, and rising awareness among patients and healthcare professionals.
One of the key drivers of the CTS management market is the advancements in diagnosis and treatment options. Over the past few years, there have been significant advances in the development of diagnostic tools that allow for earlier and more accurate diagnosis of CTS.
There have also been significant advancements in the development of treatment options for CTS. For example, somatostatin analogues (SSAs) such as octreotide and lanreotide are commonly used to control the symptoms of CTS by inhibiting the release of hormones from carcinoid tumors.
Other treatment options include chemotherapy, targeted therapy, and radiation therapy, depending on the type and stage of the tumor. As new therapies and treatment options continue to emerge, the demand for CTS management is likely to grow.
Key Takeaways from the Market Study
- The Carcinoid tumor syndrome management market is expected to grow at a value of 10.9% CAGR for the forecast period 2023-2033
- Oral route of administration is expected to hold 55% of the market share in 2023 for Carcinoid tumor syndrome management
- North America is expected to possess 44% market share for Carcinoid tumor syndrome management market in 2023.
- Europe Carcinoid tumor syndrome management market size is expected to possess 37% market share in 2023.
“The rising awareness among patients and healthcare professionals is also contributing to the growth of the CTS management market. As patients become more informed about their condition and the available treatment options, they are more likely to seek out effective management options.” states an FMI analyst
Competitive Landscape
Key players in the Carcinoid tumor syndrome management are Novartis AG, Teva Pharmaceutical Industries Ltd, Mylan N.V., Ipsen Biopharmaceuticals, Inc, Sun Pharmaceutical Industries Ltd, Amgen Inc., Entrinsic Health Solutions, Inc., Endo Pharmaceuticals Inc., Sirtex SIR-Spheres Pty Ltd, BTG International Ltd
- Mylan markets a somatostatin analog called Octreotide (brand name Sandostatin®), which is indicated for the treatment of symptoms associated with functional gastroenteropancreatic neuroendocrine tumors, including carcinoid syndrome.
- Teva markets a somatostatin analog called Lanreotide (brand name Somatuline®), which is indicated for the treatment of symptoms associated with functional gastroenteropancreatic neuroendocrine tumors, including carcinoid syndrome.
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Carcinoid tumor syndrome management market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights on the basis of Organ Affected (Small Intestine, Lungs, Rectum, Appendix, Stomach, Liver, Others) Therapy Type (Chemotherapy, Biological Therapy, Radio Therapy) Drug (Octreotide, Telotristat Etiprate, Lanreotide) Route of Administration (Oral, Injectable) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa)
Key Segments Profiled in the Carcinoid Tumor Syndrome Management Market Survey
Organ Affected:
- Small Intestine
- Lungs
- Rectum
- Appendix
- Stomach
- Liver
- Others
Therapy Type:
- Chemotherapy
- Biological Therapy
- Radio Therapy
Drug:
- Octreotide
- Telotristat Etiprate
- Lanreotide
Route of Administration:
- Oral
- Injectable
About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs
